Синдром раздраженного кишечника: неврологические аспекты патогенеза и терапии
https://doi.org/10.31146/1682-8658-ecg-231-11-128-136
Аннотация
Синдром раздраженного кишечника представляет собой хроническое рецидивирующее заболевание желудочно-кишечного тракта, характеризующееся болью в животе, вздутием живота и изменением характера стула. Хотя точная распространенность и заболеваемость зависят от используемых критериев, все исследования сходятся во мнении, что это распространенное заболевание, поражающее значительную часть населения в целом и часто обращающееся к врачам общей практики и к узким специалистам. Синдром раздраженного кишечника вызывает беспокойство, оказывая значительное негативное влияние на качество жизни и социальное функционирование многих пациентов. Синдром раздраженного кишечника является одним из наиболее часто диагностируемых заболеваний желудочно-кишечного тракта. Это представляет собой значительную нагрузку на здравоохранение и остается клинической проблемой. На протяжении многих лет синдром раздраженного кишечника описывали с разных точек зрения; от строгой болезни желудочно-кишечного тракта (медицинская модель) до более сложного полисиндромальные расстройства оси мозг-кишка (биопсихосоциальная/психосоматическая модель). Целью нашего обзора представить современные аспекты патофизиологии и лечении синдрома разждраженного кишечника.
Ключевые слова
Об авторах
Ф. А. Юсупов
Ошский государственный университет
Россия
Россия
И. Т. Ыдырысов
Ошский государственный университет
Россия
Россия
А. А. Юлдашев
Ошский государственный университет
Россия
Россия
Список литературы
1. Yusupov F.A., Yuldashev A.A. Modern aspects of vagus-induced gastroprotection and ulcerogenesis in gastric and duodenal ulcers. Experimental and Clinical Gastroenterology. 2023;215(11): 112-119. (In Russ.) doi: 10.31146/1682-8658-ecg-219-11-112-119.@@ Юсупов Ф.А., Юлдашев А.А. Современные аспекты вагус-индуцированной гастропротекции и ульцерогенеза при язвенной болезни желудка и двенадцатиперстной кишки. Экспериментальная и клиническая гастроэнтерология. 2023;215(11): 112-119. doi: 10.31146/1682-8658-ecg-219-11-112-119.
2. Boeckxstaens G., Corazziari E.S., Mearin F., Tack J. IBS and the role of otilonium bromide.Int J Colorectal Dis. 2013 Mar;28(3):295-304. doi: 10.1007/s00384-012-1598-0.
3. Ford A.C., Talley N.J. Irritable bowel syndrome. BMJ. 2012 Sep 4;345: e5836. doi: 10.1136/bmj.e5836.
4. Liu J., Hou X. A review of the irritable bowel syndrome investigation on epidemiology, pathogenesis and pathophysiology in China. J Gastroenterol Hepatol. 2011 Apr;26 Suppl 3:88-93. doi: 10.1111/j.1440-1746.2011.06641.x.
5. Spiller R., Aziz Q., Creed F., Emmanuel A., Houghton L., Hungin P., Jones R., Kumar D., Rubin G., Trudgill N., Whorwell P. Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007 Dec;56(12):1770-98. doi: 10.1136/gut.2007.119446.
6. Voß U., Lewerenz A., Nieber K. Treatment of irritable bowel syndrome: sex and gender specific aspects. Handb Exp Pharmacol. 2012;(214):473-97. doi: 10.1007/978-3-642-30726-3_21.
7. Andreev D.N., Maev I.V. The role of probiotics in current algorithms for the treatment of irritable bowel syndrome: A review. Consilium Medicum. 2023;25(5):336-342. (in Russ.) doi: 10.26442/20751753.2023.5.202131.@@ Андреев Д.Н., Маев И.В. Значение пробиотиков в современных алгоритмах терапии синдрома раздраженного кишечника. Consilium Medicum. 2023;25(5):336-342. doi: 10.26442/20751753.2023.5.202131.
8. Sandler R.S., Everhart J.E., Donowitz M. et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002 May;122(5):1500-11. doi: 10.1053/gast.2002.32978.
9. Inadomi J.M., Fennerty M.B., Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther. 2003 Oct 1;18(7):671-82. doi: 10.1046/j.1365-2036.2003.t01-1-01736.x.
10. Heitkemper M., Jarrett M., Jun S.E. Update on irritable bowel syndrome program of research. J Korean Acad Nurs. 2013 Oct;43(5):579-86. doi: 10.4040/jkan.2013.43.5.579.
11. Longstreth G.F., Yao J.F. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology. 2004 Jun;126(7):1665-73. doi: 10.1053/j.gastro.2004.02.020.
12. Ivashkin V.T., Shelygin Y.A., Baranskaya E.K. et al. Irritable bowel syndrome. Koloproktologia. 2022;21(1): 10-25. (In Russ.) doi: 10.33878/2073-7556-2022-21-1-10-25.@@ Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К. и др. Синдром раздраженного кишечника. Колопроктология. 2022;21(1):10-25. doi: 10.33878/2073-7556-2022-21-1-10-25.
13. Tillisch K., Labus J.S., Naliboff B.D., Bolus R., Shetzline M., Mayer E.A., Chang L. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol. 2005 Apr;100(4):896-904. doi: 10.1111/j.1572-0241.2005.41211.x.
14. Henderson P.K., DiPalma J.A. Diagnosing irritable bowel syndrome: a changing clinical paradigm. South Med J. 2011 Mar;104(3):195-9. doi: 10.1097/SMJ.0b013e31820bfb6c.
15. Agréus L., Svärdsudd K., Nyrén O., Tibblin G. Reproducibility and validity of a postal questionnaire. The abdominal symptom study. Scand J Prim Health Care. 1993 Dec;11(4):252-62. doi: 10.3109/02813439308994840.
16. Moayyedi P., Ford A.C. Symptom-based diagnostic criteria for irritable bowel syndrome: the more things change, the more they stay the same. Gastroenterol Clin North Am. 2011 Mar;40(1):87-103. doi: 10.1016/j.gtc.2010.12.007.
17. Manning A.P., Thompson W.G., Heaton K.W., Morris A.F. Towards positive diagnosis of the irritable bowel. Br Med J. 1978 Sep 2;2(6138):653-4. doi: 10.1136/bmj.2.6138.653.
18. Drossman D.A., McKee D.C., Sandler R.S., Mitchell C.M., Cramer E.M., Lowman B.C., Burger A.L. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology. 1988 Sep;95(3):701-8. doi: 10.1016/s0016-5085(88)80017-9.
19. Smith R.C., Greenbaum D.S., Vancouver J.B. et al. Psychosocial factors are associated with health care seeking rather than diagnosis in irritable bowel syndrome. Gastroenterology. 1990 Feb;98(2):293-301. doi: 10.1016/0016-5085(90)90817-k.
20. Locke G.R. 3rd, Weaver A.L., Melton L.J. 3rd, Talley N.J. Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol. 2004 Feb;99(2):350-7. doi: 10.1111/j.1572-0241.2004.04043.x.
21. Ivashkin V.T., Shelygin Yu.A., Baranskaya Ye.K. et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76-93. (In Russ.) doi: 10.22416/1382-4376-2017-27-5-76-93.@@ Ивашкин В.Т. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации, Ассоциации колопроктологов России по диагностике и лечению больных с синдромом раздраженного кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):76-93. doi: 10.22416/1382-4376-2017-27-5-76-93.
22. Maev I.V., Okhlobystina O.Z., Khalif I.L., Andreev D.N. Irritable bowel syndrome in the Russian Federation: results of the ROMERUS multicenter observational study. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(1):38-51. (In Russ.) doi: 10.26442/00403660.2023.01.202043.@@ Маев И.В. и др. Синдром раздраженного кишечника в российской федерации-результаты многоцентрового наблюдательного исследования ROMERUS. Терапевтический архив. 2023;95(1):38-51. doi: 10.26442/00403660.2023.01.202043.
23. Kumano H., Kaiya H., Yoshiuchi K., Yamanaka G., Sasaki T., Kuboki T.Comorbidity of irritable bowel syndrome, panic disorder, and agoraphobia in a Japanese representative sample. Am J Gastroenterol. 2004 Feb;99(2):370-6. doi: 10.1111/j.1572-0241.2004.04048.x.
24. Bardhan K.D., Bodemar G., Geldof H., Schütz E., Heath A., Mills J.G., Jacques L.A. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2000 Jan;14(1):23-34. doi: 10.1046/j.1365-2036.2000.00684.x.
25. Agréus L., Svärdsudd K., Nyrén O., Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995 Sep;109(3):671-80. doi: 10.1016/ 0016-5085(95)90373-9.
26. Corsetti M., Caenepeel P., Fischler B., Janssens J., Tack J. Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol. 2004 Jun;99(6):1152-9. doi: 10.1111/j.1572-0241.2004.30040.x.
27. Ragnarsson G., Bodemar G. Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients’ description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol. 1998 May;10(5):415-21. doi: 10.1097/00042737-199805000-00011.
28. Chey W.Y., Jin H.O., Lee M.H., Sun S.W., Lee K.Y. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol. 2001 May;96(5):1499-506. doi: 10.1111/j.1572-0241.2001.03804.x.
29. Clemens C.H., Samsom M., Roelofs J.M., van Berge Henegouwen G.P., Smout A.J. Association between pain episodes and high amplitude propagated pressure waves in patients with irritable bowel syndrome. Am J Gastroenterol. 2003 Aug;98(8):1838-43. doi: 10.1111/j.1572-0241.2003.07541.x.
30. Accarino A.M., Azpiroz F., Malagelada J.R. Modification of small bowel mechanosensitivity by intestinal fat. Gut. 2001 May;48(5):690-5. doi: 10.1136/gut.48.5.690.
31. Francis C.Y., Duffy J.N., Whorwell P.J., Morris J. High prevalence of irritable bowel syndrome in patients attending urological outpatient departments. Dig Dis Sci. 1997 Feb;42(2):404-7. doi: 10.1023/a:1018838507545.
32. Prior A., Wilson K., Whorwell P.J., Faragher E.B. Irritable bowel syndrome in the gynecological clinic. Survey of 798 new referrals. Dig Dis Sci. 1989 Dec;34(12):1820-4. doi: 10.1007/BF01536698.
33. Lubrano E., Iovino P., Tremolaterra F., Parsons W.J., Ciacci C., Mazzacca G. Fibromyalgia in patients with irritable bowel syndrome. An association with the severity of the intestinal disorder.Int J Colorectal Dis. 2001 Aug;16(4):211-5. doi: 10.1007/s003840100299.
34. Whitehead W.E., Palsson O., Jones K.R. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002 Apr;122(4):1140-56. doi: 10.1053/gast.2002.32392.
35. Walker E.A., Gelfand A.N., Gelfand M.D., Green C., Katon W.J. Chronic pelvic pain and gynecological symptoms in women with irritable bowel syndrome. J Psychosom Obstet Gynaecol. 1996 Mar;17(1):39-46. doi: 10.3109/01674829609025662.
36. Williams R.E., Hartmann K.E., Sandler R.S., Miller W.C., Steege J.F. Prevalence and characteristics of irritable bowel syndrome among women with chronic pelvic pain. Obstet Gynecol. 2004 Sep;104(3):452-8. doi: 10.1097/01.AOG.0000135275.63494.3d.
37. Aaron L.A., Burke M.M., Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000 Jan 24;160(2):221-7. doi: 10.1001/archinte.160.2.221.
38. Vandvik P.O., Wilhelmsen I., Ihlebaek C., Farup P.G.Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications. Aliment Pharmacol Ther. 2004 Nov 15;20(10):1195-203. doi: 10.1111/j.1365-2036.2004.02250.x.
39. Sykes M.A., Blanchard E.B., Lackner J., Keefer L., Krasner S. Psychopathology in irritable bowel syndrome: support for a psychophysiological model. J Behav Med. 2003 Aug;26(4):361-72. doi: 10.1023/a:1024209111909.
40. Pan G., Lu S., Ke M., Han S., Guo H., Fang X. Epidemiologic study of the irritable bowel syndrome in Beijing: stratified randomized study by cluster sampling. Chin Med J (Engl). 2000 Jan;113(1):35-9.
41. Bennett E.J., Piesse C., Palmer K., Badcock C.A., Tennant C.C., Kellow J.E. Functional gastrointestinal disorders: psychological, social, and somatic features. Gut. 1998 Mar;42(3):414-20. doi: 10.1136/gut.42.3.414.
42. North C.S., Downs D., Clouse R.E., Alrakawi A., Dokucu M.E., Cox J., Spitznagel E.L., Alpers D.H. The presentation of irritable bowel syndrome in the context of somatization disorder. Clin Gastroenterol Hepatol. 2004 Sep;2(9):787-95. doi: 10.1016/s1542-3565(04)00350-7.
43. Drossman D.A., Li Z., Toner B.B. et al. Functional bowel disorders. A multicenter comparison of health status and development of illness severity index. Dig Dis Sci. 1995 May;40(5):986-95. doi: 10.1007/BF02064187.
44. Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997 Apr;11(2):395-402. doi: 10.1046/j.1365-2036.1997.142318000.x.
45. Davidson M., Waserman R. The iritable colon of childhood (chronic nonspecific diarrhea syndrome). J Pediatr. 1966 Dec;69(6):1027-38. doi: 10.1016/s0022-3476(66)80292-5.
46. Kalantar J.S., Locke G.R. 3rd, Zinsmeister A.R., Beighley C.M., Talley N.J. Familial aggregation of irritable bowel syndrome: a prospective study. Gut. 2003 Dec;52(12):1703-7. doi: 10.1136/gut.52.12.1703.
47. Levy R.L., Whitehead W.E., Walker L.S., Von Korff M., Feld A.D., Garner M., Christie D. Increased somatic complaints and health-care utilization in children: effects of parent IBS status and parent response to gastrointestinal symptoms. Am J Gastroenterol. 2004 Dec;99(12):2442-51. doi: 10.1111/j.1572-0241.2004.40478.x.
48. Park M.I., Camilleri M. Genetics and genotypes in irritable bowel syndrome: implications for diagnosis and treatment. Gastroenterol Clin North Am. 2005 Jun;34(2):305-17. doi: 10.1016/j.gtc.2005.02.009.
49. Saito Y.A., Cremonini F., Talley N.J. Association of the 1438G/A and 102T/C polymorphism of the 5-HT2A receptor gene with irritable bowel syndrome 5-HT2A gene polymorphism in irritable bowel syndrome. J Clin Gastroenterol. 2005 Oct;39(9):835; author reply 835-6. doi: 10.1097/01.mcg.0000177239.90005.b5.
50. Camilleri M., Atanasova E., Carlson P.J., Ahmad U., Kim H.J., Viramontes B.E., McKinzie S., Urrutia R. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2002 Aug;123(2):425-32. doi: 10.1053/gast.2002.34780.
51. van der Voort I.R., Osmanoglou E., Seybold M. et al. Electrogastrography as a diagnostic tool for delayed gastric emptying in functional dyspepsia and irritable bowel syndrome. Neurogastroenterol Motil. 2003 Oct;15(5):467-73. doi: 10.1046/j.1365-2982.2003.00433.x.
52. van der Voort I.R., Osmanoglou E., Seybold M., Heymann-Mönnikes I., Tebbe J., Wiedenmann B., Klapp B.F., Mönnikes H. Electrogastrography as a diagnostic tool for delayed gastric emptying in functional dyspepsia and irritable bowel syndrome. Neurogastroenterol Motil. 2003 Oct;15(5):467-73. doi: 10.1046/j.1365-2982.2003.00433.x.
53. Simrén M., Castedal M., Svedlund J., Abrahamsson H., Björnsson E. Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS) [correction of (IBD)]. Dig Dis Sci. 2000 Nov;45(11):2151-61. doi: 10.1023/a:1010770302403.
54. Kellow J.E., Phillips S.F., Miller L.J., Zinsmeister A.R. Dysmotility of the small intestine in irritable bowel syndrome. Gut. 1988 Sep;29(9):1236-43. doi: 10.1136/gut.29.9.1236.
55. Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002 Dec;123(6):2108-31. doi: 10.1053/gast.2002.37095.
56. Woolf C.J. Somatic pain - pathogenesis and prevention. Br J Anaesth. 1995 Aug;75(2):169-76. doi: 10.1093/bja/75.2.169.
57. Coutinho S.V., Su X., Sengupta J.N., Gebhart G.F. Role of sensitized pelvic nerve afferents from the inflamed rat colon in the maintenance of visceral hyperalgesia. Prog Brain Res. 2000;129:375-87. doi: 10.1016/S0079-6123(00)29029-8.
58. Treede R.D., Meyer R.A., Raja S.N., Campbell J.N. Peripheral and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol. 1992;38(4):397-421. doi: 10.1016/0301-0082(92)90027-c.
59. Moriarty K.J., Dawson A.M. Functional abdominal pain: further evidence that whole gut is affected. Br Med J (Clin Res Ed). 1982 Jun 5;284(6330):1670-2. doi: 10.1136/bmj.284.6330.1670.
60. WAND-TETLEY J.I. Historical methods of counter-irritation. Ann Phys Med. 1956 Jul;3(3):90-9. doi: 10.1093/rheumatology/iii.3.90.
61. Howell S., Poulton R., Talley N.J. The natural history of childhood abdominal pain and its association with adult irritable bowel syndrome: birth-cohort study. Am J Gastroenterol. 2005 Sep;100(9):2071-8. doi: 10.1111/j.1572-0241.2005.41753.x.
62. Hammer J., Eslick G.D., Howell S.C., Altiparmak E., Talley N.J. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut. 2004 May;53(5):666-72. doi: 10.1136/gut.2003.021857.
63. Francis C.Y., Whorwell P.J. Bran and irritable bowel syndrome: time for reappraisal. Lancet. 1994 Jul 2;344(8914):39-40. doi: 10.1016/s0140-6736(94)91055-3.
64. Stefanini G.F., Prati E., Albini M.C., Piccinini G., Capelli S., Castelli E., Mazzetti M., Gasbarrini G. Oral disodium cromoglycate treatment on irritable bowel syndrome: an open study on 101 subjects with diarrheic type. Am J Gastroenterol. 1992 Jan;87(1):55-7.
65. Atkinson W., Sheldon T.A., Shaath N., Whorwell P.J. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. 2004 Oct;53(10):1459-64. doi: 10.1136/gut.2003.037697.
66. Zar S., Benson M.J., Kumar D. Food-specific serum IgG4 and IgE titers to common food antigens in irritable bowel syndrome. Am J Gastroenterol. 2005 Jul;100(7):1550-7. doi: 10.1111/j.1572-0241.2005.41348.x.
67. Pitz M., Cheang M., Bernstein C.N. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005 Mar;3(3):237-47. doi: 10.1016/s1542-3565(04)00626-3.
68. O’Malley P.G., Jackson J.L., Santoro J., Tomkins G., Balden E., Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract. 1999 Dec;48(12):980-90. PMID: 10628579.
69. Cann P.A., Read N.W., Holdsworth C.D., Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci. 1984 Mar;29(3):239-47. doi: 10.1007/BF01296258.
70. De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut. 2004 Oct;53(10):1520-35. doi: 10.1136/gut.2003.035568.
71. Tack J., Broekaert D., Fischler B., Van Oudenhove L., Gevers A.M., Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006 Aug;55(8):1095-103. doi: 10.1136/gut.2005.077503.
72. Glaxo Wellcome withdraws irritable bowel syndrome medication. FDA Consum. 2001 Jan-Feb;35(1):3. PMID: 11930921.
Рецензия
Для цитирования:
Юсупов Ф.А., Ыдырысов И.Т., Юлдашев А.А. Синдром раздраженного кишечника: неврологические аспекты патогенеза и терапии. Экспериментальная и клиническая гастроэнтерология. 2024;(11):128-136. https://doi.org/10.31146/1682-8658-ecg-231-11-128-136
For citation:
Yusupov F.A., Ydyrysov I.T., Yuldashev A.A. Irritable bowel syndrome: neurological aspects of pathogenesis and therapy. Experimental and Clinical Gastroenterology. 2024;(11):128-136. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-231-11-128-136
Просмотров:
52
Послать статью по эл. почте 